Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on May 23rd, 2016 by J.-P. Clement MDPharmacovigilance
The FDA IND reporting rule[i], mandatory since March 2011, has had a major impact on the sponsor’s responsibilities to report safety information representing a potential change in the risk profile for products that are under investigation. (more…)
Posted on May 19th, 2016 by Ros CheethamPharma R&D
I’m an avid sailor, and on our boat we have an amazing device known as a water-maker. It is probably one of the most useful pieces of equipment on board for long cruises, as it takes in sea water, and, through a process of reverse osmosis, provides potable drinking water. (more…)
Posted on May 6th, 2016 by Joyce de LangenPharmacovigilance
After our recent webinar, Elsevier received several questions from attendees. During the next few weeks, we will discuss some of the questions in more detail. (more…)
Posted on May 5th, 2016 by Maria ShkrobPharma R&D
When you compare PubMed search results for rare diseases, such as “congenital hyperinsulinism” (767), schwannomatosis (250) or “Mabry syndrome” (34), to that of “diabetes” (542,987), “heart attack” (217,694) or “obesity” (237,307), the disparity in attention becomes much more obvious. (more…)
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.